Yong Eun

Dr. Yong Eun

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in Science Advances
Verified
Journal Article
Open access
NZNan Zhang
Nan Zhang
HZHongjie Zhang
Hongjie Zhang
LKLiakot A. Khan
Liakot A. Khan
GJGholamali Jafari
Gholamali Jafari
YEYong Eun
Yong Eun
VGVerena Gobel
Verena Gobel
In prevailing epithelial polarity models, membrane-based polarity cues (e.g., the partitioning-defective PARs) position apicobasal cellular membrane domains. Intracellular vesicular trafficking expands these domains by sorting polarized cargo toward them. How the polarity cues themselves are polarized in epithelia and how sorting confers long-range apicobasal directionality to vesicles is still unclear. Here, a systems-based approach using two-tiered C. elegans genomics-genetics screens identifies trafficking molecules that are not implicated in apical sorting yet polarize apical membrane and PAR complex components. Live tracking of polarized membrane biogenesis indicates that the biosynthetic-secretory pathway, linked to recycling routes, is asymmetrically oriented toward the apical domain during this domain’s biosynthesis, and that this directionality is regulated upstream of PARs and independent of polarized target membrane domains. This alternative mode of membrane polarization could offer solutions to open questions in current models of epithelial polarity and polarized trafficking.

14 July 2026 in Neurology
Verified
Journal Article
Closed access
YEYong Eun
Yong Eun
SBSuhwan Bong
Suhwan Bong
HKHyun Yong Koh
Hyun Yong Koh
RTRhonda Trousdale
Rhonda Trousdale
YCYoung Min Cho
Young Min Cho
SLSoon-Tae Lee
Soon-Tae Lee
Adult-onset seizure reflects the burden of acquired brain insults, but established disease-modifying preventive strategies are limited. We evaluated whether semaglutide initiation is associated with a lower incidence of adult-onset seizure compared to sodium-glucose cotransporter 2 (SGLT2) inhibitors and other glucose-lowering drugs (GLDs) in adults with type 2 diabetes. Using the All of Us Research Program, we emulated a population-based target trial in new-user, active-comparator cohorts from January 2018 to October 2023. We compared semaglutide versus other GLDs and semaglutide versus SGLT2 inhibitors. Incident epilepsy or seizure was identified from diagnostic codes. Effects were estimated using inverse probability of treatment weighting (IPTW) with weighted Cox models and targeted maximum likelihood estimation (TMLE). Subgroup and sensitivity analyses with multiple outcome definitions and analytic approaches were conducted to assess the robustness of findings. We evaluated mediation through hemoglobin A1c (HbA1c) and body mass index (BMI) using the longitudinal Vansteelandt framework. We analyzed 10,213 patients in the semaglutide (n=2,586, mean age, 60.1 years; 56.8% female) versus other GLDs cohort (n=7,627, mean age, 63.7 years; 54.2% female) and 8,605 patients in the semaglutide (n=2,814, mean age, 60.5 years; 66.2% female) versus SGLT2i cohort (n=5,791, mean age, 64.4 years; 47.3% female). Semaglutide was associated with a lower risk of adult-onset seizure compared to other GLDs (weighted HR, 0.44 [95% CI, 0.25-0.79]; 4-year risk difference, −1.78% [95% CI, −2.58 to −0.98]) and SGLT2i (weighted HR, 0.48 [95% CI, 0.27-0.85]; 4-year risk difference, -1.46% [95% CI, −2.41 to −0.51]). TMLE estimated risk differences per 1,000 persons of −14.20 (95% CI, −18.33 to −10.07) versus other GLDs and −7.62 (95% CI, −11.65 to −3.60) versus SGLT2i, corresponding to numbers needed to treat of 70 and 131, respectively. Mediation was minimal for HbA1c (2.4% vs other GLDs; 6.5% vs SGLT2i) and BMI (0% vs other GLDs; 0.7% vs SGLT2i). Semaglutide initiation was associated with a lower risk of adult-onset seizure compared to SGLT2i and other GLDs in patients with type 2 diabetes, independent of glycemic and weight effects. Residual confounding, low event counts, and shorter follow-up limit causal interpretation. This study provides Class II evidence that semaglutide use was associated with a lower risk of adult-onset seizures compared to other glucose lowering drugs and sodium-glucose cotransporter-2 inhibitors.

5 June 2025 in World Journal of Gastrointestinal Pharmacology and Therapeutics
Verified
Journal Article
Open access
YEYong Eun
Yong Eun
JCJoan Culpepper-Morgan
Joan Culpepper-Morgan
AAAbiodun M Akanmode
Abiodun M Akanmode
MTMyint B Thu
Myint B Thu
ALAprilee A Sta Lucia
Aprilee A Sta Lucia
RTRhonda K Trousdale
Rhonda K Trousdale
BACKGROUND Patients with inflammatory bowel disease (IBD) are at an increased risk of bacterial pneumonia, contributing to significant morbidity and mortality. While previous studies have identified various risk factors, including medications and comorbidities, the independent contribution of IBD to pneumonia risk remains unclear. We hypothesized that the increased pneumonia risk is primarily driven by factors other than IBD itself. AIM To investigate the relative contributions of IBD, comorbidities, and medications to pneumonia risk in patients with IBD. METHODS We conducted a retrospective cohort study using the All of Us Research Program database (2010-2022). We matched 2810 participants with IBD 1:1 with controls using four propensity score models: (1) Demographics/Lifestyle only; (2) Plus comorbidities; (3) Plus medications; and (4) All factors combined. Then we used Cox proportional hazards models to assess pneumonia risk and logistic regression to evaluate risk factors. RESULTS In the primary analysis of 5620 matched participants, IBD was not independently associated with increased pneumonia risk [hazard ratio (HR) = 1.07, 95%CI: 0.84-1.35] when matched for all factors. However, participants with IBD had significantly higher risk (HR = 2.08, 95%CI: 1.56-2.78) when matched only for demographics and lifestyle factors. Within the IBD cohort, a high comorbidity burden (Charlson Comorbidity Index ≥ 10) [odds ratio (OR) = 12.20, 95%CI: 6.69-23.00] and systemic steroid use (OR = 2.26, 95%CI: 1.21-4.64) were independently associated with increased pneumonia risk. CONCLUSION Comorbidities and systemic steroids, rather than IBD itself, drive pneumonia risk. Management should focus on these factors and prioritize vaccination in high-risk patients.

2 November 2021 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
YEYong Eun
Yong Eun
JKJIHYUN KIM
JIHYUN KIM
SLSeon Hee Lim
Seon Hee Lim
YAYo Han Ahn
Yo Han Ahn
HKHee Gyung Kang
Hee Gyung Kang
IHIl-Soo Ha
Il-Soo Ha

2 November 2021 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
YEYong Eun
Yong Eun
JKJIHYUN KIM
JIHYUN KIM
SLSeon Hee Lim
Seon Hee Lim
YAYo Han Ahn
Yo Han Ahn
HKHee Gyung Kang
Hee Gyung Kang
IHIl-Soo Ha
Il-Soo Ha

21 August 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
YEYong Eun
Yong Eun
MTMarie Thearle
Marie Thearle
JKJoon Hee Kim
Joon Hee Kim
RTRhonda Trousdale
Rhonda Trousdale
JCJoan Culpepper-Morgan
Joan Culpepper-Morgan
Background/Objectives: Social determinants of health are implicated in metabolic dysfunction–associated steatotic liver disease (MASLD), yet longitudinal evidence on incident disease is scarce, and whether individual- and community-level determinants act independently remains unclear. The objective of this study was to examine whether individual food insecurity and neighborhood deprivation are independently associated with incident MASLD. Methods: In this retrospective cohort of 40,693 U.S. adults without baseline MASLD in the diverse NIH All of Us Research Program, food insecurity (two-item Hunger Vital Sign) and neighborhood deprivation (validated five-domain composite) were co-primary exposures, with incident MASLD ascertained from validated diagnostic codes. Proportional hazards models were adjusted for demographic, socioeconomic, and metabolic factors, including obesity. Results: Over 116,220 person-years, 1240 (3.0%) participants developed MASLD. Both associations remained significant after adjustment for demographic, socioeconomic, and major metabolic risk factors, including obesity (food insecurity adjusted hazard ratio [aHR] 1.32, 95% CI 1.13–1.53; neighborhood deprivation aHR 1.20, 95% CI 1.05–1.37). Unadjusted cumulative incidence was highest among participants with both exposures and lowest among those with neither. Findings were consistent across sensitivity analyses; the food-insecurity association remained when neighborhood disadvantage was specified with a census-based index. Conclusions: Food insecurity and neighborhood deprivation were independently associated with higher incidence of MASLD. Nutrition-focused, equity-oriented interventions warrant evaluation to reduce MASLD burden and advance health equity.